Background Rheumatoid arthritis (RA) is a chronic disease that implies high direct and indirect costs for the health system (1,2). According to the needs of the health care system, the clinical interests and the national regulatory framework, it was developed a national registry information of RA patients (3).
Objectives To show how a registry of information that would meet the RA situation was developed and to present the results obtained from the analysis of the Registry on this first year.
Methods A national RA Registry was created after a comprehensive literature review to identify the relevant variables to determine monitoring indicators used by health insurers and health services providers in the attention of patients with RA. Variables were selected and defined by an agreement with clinical experts, thematic and methodological experts and were evaluated by the Ministry of Health in order to review and approve the structure to gather the information.
Results A structure of 89 variables contained was defined. All entities must report annually to the Registry all the patients with a diagnosis of RA, their clinical and demographic characteristics, and the process of care and costs (3). On its first year the Registry provided a baseline of the disease situation of 68.357 patients with RA. Prevalence, incidence, state of disease and drugs including synthetic and biologic DMARDs were analyzed (Table 1). Most important results were: mean age 57 years; relation women: men 5.2:1; age at onset of disease: 36 years, mean evolution time of disease: 7 years; population with DAS 28 measured 45.6%; mean DAS-28 2.8; percentage of the patient with DMARD therapy 78.9% and bDMARD 16.5%.
Conclusions A national Registry supported by an official policy, with data from the real world provided for healthcare insurers gives an opportunity to obtain a global vision and to identify failures and strengths in the attention process of RA, and to develop indicators to obtain better outcomes. In the future, through continuous efforts towards improving the quality of care provided, these will allow to monitoring and decreasing the burden of RA in the country and may serve as a model to other countries.
Muñetόn GA, Quintana G. La epidemiología de la artritis reumatoide. Rev Colomb Reumatol. 2015 Sep [cited 2016 Jul 25];22(3):145–7. Available from: http://www.elsevier.es/es-revista-revista-colombiana-reumatologia-374-articulo-la-epidemiologia-artritis-reumatoide-S0121812315000845.
Quintana G., Restrepo JP, Cáceres H, Rueda JD. Economic evaluation of the treatment of rheumatoid arthritis with anti-TNF biological therapy in Colombia. Acta Médica Colomb. 2011;36(1):24–9. Available from: http://www.scielo.org.co/pdf/amc/v36n1/v36n1a05.pdf.
MSPS. Resolucion No. 1393. 2015. p. 14.
Disclosure of Interest None declared